Welcome to Markets Desk, here's what's moving the needle right now.
Eli Lilly has broken ground on a six point five billion dollar manufacturing facility in Houston, Texas, set to produce active pharmaceutical ingredients for its weight-loss drug Foundayo and other small-molecule therapies. The move signals Lilly's commitment to domestic production capacity as demand for its obesity portfolio continues to outpace supply.
Shifting to the labor market, a growing number of professionals are finding themselves quietly recast as AI supervisors without any corresponding change in title or compensation. Workers hired to teach, write, code, or design are spending more of their hours managing autonomous tools than practicing the craft they were brought in for — a structural shift that's rewriting job descriptions without rewriting pay stubs.
And on the trade front, President Trump's push to source potash from Belarus is running into a hard geographic reality. Canada's premier is warning that Belarusian fertilizer would need to transit through Russia to reach American markets, complicating any effort to use the move as leverage against Ottawa. Canada currently supplies the vast majority of American potash imports, and Belarus says its current output is already contracted, leaving little room to maneuver.
That's the tape. Markets Desk, signing off the floor.
